• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Multiple Sclerosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019 - Product Image

Multiple Sclerosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

  • Published: February 2012
  • 141 pages
  • GlobalData

FEATURED COMPANIES

  • AB Science
  • Abbott
  • Biogen Idec
  • Merck KGaA/Merck Serono
  • Nuron Biotech
  • Sanofi
  • MORE

Multiple Sclerosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, “Multiple Sclerosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Multiple Sclerosis market. The report identifies the key trends shaping and driving the global Multiple Sclerosis market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Multiple Sclerosis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Multiple Sclerosis market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Multiple READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Multiple Sclerosis Therapeutics - Introduction
2.1 Disease Overview
2.2 Epidemiology
2.2.1 Prevalence
2.2.2 Prevalence by Gender
2.2.3 Prevalence by Age Group
2.2.4 Prevalence by Disease Severity
2.2.5 Quality of Life (QoL)
2.2.6 Comorbidities in MS
2.2.7 Pharmaco-Economic Burden
2.3 Etiology
2.4 Signs and Symptoms
2.5 Diagnosis
2.5.1 Diagnostic Criteria:
2.6 Treatment and Management Pattern
2.6.1 Treatment for Acute Relapses of MS Symptoms
2.6.2 Treatment for Specific MS Symptoms
2.6.3 Treatment to Slow the Progression of MS (DMDs)
2.7 Rehabilitation
2.7.1 Physical Therapy
2.7.2 Occupational Therapy
2.7.3 Speech Therapy
2.8 Complementory and Alternative Therapy
2.9 Surgical Care
2.10 Referral Pathway
2.11 GlobalData Pipeline Report Guidance
3 Multiple Sclerosis Therapeutics - Market Characterization
3.1 Multiple Sclerosis Therapeutics Market Size (2006 - 2011) - Global
3.2 Multiple Sclerosis Therapeutics Market Forecast (2011–2019) – Global
3.3 Multiple Sclerosis Therapeutics Market Size (2006–2011) – The US
3.4 Multiple Sclerosis Therapeutics Market Forecast (2011–2019) – The US
3.5 Multiple Sclerosis Therapeutics Market Size (2006–2011) – France
3.6 Multiple Sclerosis Therapeutics Market Forecast (2011–2019) – France
3.7 Multiple Sclerosis Therapeutics Market Size (2006–2011) – Germany
3.8 Multiple Sclerosis Therapeutics Market Forecast (2011–2019) – Germany
3.9 Multiple Sclerosis Therapeutics Market Size (2006–2011) – Italy
3.10 Multiple Sclerosis Therapeutics Market Forecast (2011–2019) – Italy
3.11 Multiple Sclerosis Therapeutics Market Size (2006–2011) – Spain
3.12 Multiple Sclerosis Therapeutics Market Forecast (2011–2019) – Spain
3.13 Multiple Sclerosis Therapeutics Market Size (2006–2011) – The UK
3.14 Multiple Sclerosis Therapeutics Market Forecast (2011–2019) – The UK
3.15 Multiple Sclerosis Therapeutics Market Size (2006–2011) – Japan
3.16 Multiple Sclerosis Therapeutics Market Forecast (2011–2019) – Japan
3.17 Drivers and Barriers for the Multiple Sclerosis Therapeutics Market
3.17.1 Drivers for the Multiple Sclerosis Therapeutics Market
3.17.2 Barriers for the Multiple Sclerosis Therapeutics Market
3.17.3 Opportunity and Unmet Need Analysis
3.18 Key Takeaway
4 Multiple Sclerosis Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the Multiple Sclerosis Therapeutics Market
4.3.1 Gilenya (fingolimod)
4.3.2 Tysabri (natalizumab)
4.3.3 Copaxone (Glatarimer Acetate or GA or Copolymer 1)
4.3.4 Avonex (Interferon beta-1a) IM Injection
4.3.5 Rebif (Interferon beta-1a)
4.3.6 Betaseron/Betaferon (Interferon beta-1b)
4.4 Key Takeaway
5 Multiple Sclerosis Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Multiple Sclerosis Therapeutics Pipeline – Pipeline by Phase of Development
5.3.1 Multiple Sclerosis Therapeutics – Filed Pipeline
5.3.2 Multiple Sclerosis Therapeutics – Phase III Pipeline
5.3.3 Multiple Sclerosis Therapeutics – Phase II/III Pipeline
5.3.4 Multiple Sclerosis Therapeutics – Phase II Pipeline
5.3.5 Multiple Sclerosis Therapeutics – Phase I/II Pipeline
5.3.6 Multiple Sclerosis Therapeutics – Phase I Pipeline
5.3.7 Multiple Sclerosis Therapeutics – Phase 0 Pipeline
5.3.8 Multiple Sclerosis Therapeutics – Pre-clinical Pipeline
5.3.9 Technology Trends Analytic Framework
5.4 Multiple Sclerosis Therapeutics Market – Pipeline by Mechanism of Action
5.5 Multiple Sclerosis Therapeutics – Promising Drugs under Clinical Development
5.6 Molecule Profile for Promising Drugs under Clinical Development
5.6.1 Aubagio (Teriflunomide)
5.6.2 Masitinib (AB1010)
5.6.3 Pegylated Interferon Beta-1a (BIIB017)
5.6.4 RG1594 (ocrelizumab)
5.6.5 Venilon
5.6.6 Laquinimod
5.6.7 NU100 (interferon beta-1b)
5.6.8 Daclizumab High-yield Process (DAC HYP)
5.6.9 Dimethyl Fumarate (BG00012)
5.6.10 Revimmune
5.6.11 Lemtrada (alemtuzumab)
5.7 Key Takeaway
6 Multiple Sclerosis Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in Multiple Sclerosis Therapeutics Clinical Trials
7 Strategic Assessment
7.1 Key Events Impacting on the Future Market
7.2 Multiple Sclerosis Therapeutics: Implications for Future Market Competition
8 Multiple Sclerosis Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Sanofi
8.2.2 Merck KGaA/Merck Serono
8.2.3 Biogen Idec
8.2.4 Teva Pharmaceutical Industries (Teva)
8.2.5 Nuron Biotech
8.2.6 F. Hoffmann-La Roche (Roche)
8.2.7 Teijin Pharma
8.2.8 Accentia Biopharmaceuticals
8.2.9 AB Science
8.2.10 Abbott
9 Multiple Sclerosis Therapeutics - Licensing and Partnership Deals
10 Multiple Sclerosis Therapeutics - Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Prevalence of MS in Europe
Table 2: Prevalence of MS in Italy
Table 3: Prevalence (in population aged >19 years) per 100,000 by Age Group
Table 4: Breakdown of the Total Treatment Costs of MS ($)
Table 5: Annual Costs of MS
Table 6: Estimated Costs of MS by Country (€m), 2005
Table 7: Immunopathologic Phenotypes of Plaques
Table 8: Proposed Immunotherapeutic Strategies in MS
Table 9: Signs and Symptoms
Table 10: Poser Criteria of Diagnosis of MS
Table 11: The 2010 McDonald Criteria of Diagnosis of MS
Table 12: Treatment for Specific MS Symptoms
Table 13: Multiple Sclerosis Therapeutics Market, Global, Revenue ($m), 2006-2011
Table 14: Multiple Sclerosis Therapeutics Market, Global, Forecast ($m), 2011-2019
Table 15: Multiple Sclerosis Therapeutics Market, the US, Revenue ($m), 2006-2011
Table 16: Multiple Sclerosis Therapeutics Market, the US, Forecast ($m), 2011-2019
Table 17: Multiple Sclerosis Therapeutics Market, France, Revenue ($m), 2006-2011
Table 18: Multiple Sclerosis Therapeutics Market, France, Forecast ($m), 2011-2019
Table 19: Multiple Sclerosis Therapeutics Market, Germany, Revenue ($m), 2006-2011
Table 20: Multiple Sclerosis Therapeutics Market, Germany, Forecast ($m), 2011-2019
Table 21: Multiple Sclerosis Therapeutics Market, Italy, Revenue ($m), 2006-2011
Table 22: Multiple Sclerosis Therapeutics Market, Italy, Forecast ($m), 2011-2019
Table 23: Multiple Sclerosis Therapeutics Market, Spain, Revenue ($m), 2006-2011
Table 24: Multiple Sclerosis Therapeutics Market, Spain, Forecast ($m), 2011-2019
Table 25: Multiple Sclerosis Therapeutics Market, the UK, Revenue ($m), 2006-2011
Table 26: Multiple Sclerosis Therapeutics Market, the UK, Forecast ($m), 2011-2019
Table 27: Multiple Sclerosis Therapeutics Market, Japan, Revenue ($m), 2006-2011
Table 28: Multiple Sclerosis Therapeutics Market, Japan, Forecast ($m), 2011-2019
Table 29: Clinical and MRI Results of Study 1
Table 30: Clinical and MRI Results of Study 2
Table 31: Study 1 Efficacy Results
Table 32: Study 2 Efficacy Results
Table 33: Study 4 MRI Results
Table 34: Multiple Sclerosis Therapeutics, Filed Pipeline, 2011
Table 35: Multiple Sclerosis Therapeutics, Phase III Pipeline, 2011
Table 36: Multiple Sclerosis Therapeutics, Phase II/III Pipeline, 2011
Table 37: Multiple Sclerosis Therapeutics, Phase II Pipeline, 2011
Table 38: Multiple Sclerosis Therapeutics, Phase I/II Pipeline, 2011
Table 39: Multiple Sclerosis Therapeutics, Phase I Pipeline, 2011
Table 40: Multiple Sclerosis Therapeutics, Phase 0 Pipeline, 2011
Table 41: Multiple Sclerosis Therapeutics, Pre-clinical Pipeline, 2011
Table 42: Multiple Sclerosis Therapeutics, Discovery Pipeline, 2011
Table 43: Phase III Clinical Trail Details of Aubagio (Teriflunomide)
Table 44: Multiple Sclerosis Therapeutics, Clinical Trials by Country, 2012
Table 45: Multiple Sclerosis Therapeutics, Clinical Trials by Phase, 2012
Table 46: Multiple Sclerosis Therapeutics, Clinical Trials by Status, 2012
Table 47: Multiple Sclerosis Therapeutics, Prominent Sponsors, 2012
Table 48: Multiple Sclerosis Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2012
Table 49: Sanofi Pharmaceuticals - Neuroscience Pipeline, 2011
Table 50: Sanofi Pharmaceuticals - MS Pipeline, 2011
Table 51: Merck KGaA - MS Pipeline, 2011
Table 52: Biogen Idec - Neuroscience Pipeline, 2011
Table 53: Biogen Idec - MS Pipeline, 2011
Table 54: Teva Pharmaceutical Industries - MS Pipeline, 2011
Table 55: Nuron Biotech - MS Pipeline, 2011
Table 56: F. Hoffmann-La Roche - Neuroscience Pipeline, 2011
Table 57: F. Hoffmann-La Roche - MS Pipeline, 2011
Table 58: Teijin Pharma - MS Pipeline, 2011
Table 59: Accentia BioPharmaceuticals - MS Pipeline, 2011
Table 60: AB Science - MS Pipeline, 2011
Table 61: Abbott - Neuroscience Pipeline, 2011
Table 62: Abbott - MS Pipeline, 2011
Table 63: Multiple Sclerosis Therapeutics, Global, Deals, 2009-2011

1.2 List of Figures
Figure 1: Representation of Myelin Sheath Degeneration in MS
Figure 2: Disability with Time Period in Different Stages of MS
Figure 3: Prevalence of MS by Region (per 100,000)
Figure 4: KOL Insights, Prevalence of MS in the US
Figure 5: Prevalence by Disease Severity
Figure 6: Estimated Costs of MS by Country (€m), 2005
Figure 7: Immunopathogenetic Steps in MS and Mediators
Figure 8: Immunopathogenetic Steps in MS and Mediators
Figure 9: Classification of MS Lesion Pattern
Figure 10: Neural Degeneration and MRI images of Developing Lesions Observed in MS Patients
Figure 11: Histology and MRI images Observed in MS Patients
Figure 12: Immunologic Targets in MS via Pathogenesis
Figure 13: Percentage of Symptoms Presented by People with MS
Figure 14: KOL Insights, Recent Trend in the Diagnosis of MS
Figure 15: MRI of MS Patient
Figure 16: KOL Insights, Usage of DMDs in Management of MS
Figure 17: Recommended Dosage of Corticosteroids
Figure 18: KOL Insights, Treatment Options for Managing MS
Figure 19: Eligibility Criteria for the Department of Health’s Risk-sharing Scheme
Figure 20: KOL Insights, Use of Guidelines for MS Treatement
Figure 21: Recommended Dosage of Interferon-beta
Figure 22: Recommended Dosage of Disease Modifying Drugs (DMDs)
Figure 23: KOL Insights, Efficacy and Safety Profile of DMDs
Figure 24: Pathway for Management of Sub-optimal Response or Side-effects in Patients Taking DMD Treatment
Figure 25: Decision-Making Therapeutic Algorithm for MS Treatment
Figure 26: Referral Pathway
Figure 27: Multiple Sclerosis Therapeutics Market, Global, Revenue ($m), 2006–2011
Figure 28: Multiple Sclerosis Therapeutics Market, Global, Forecast ($m), 2011–2019
Figure 29: Multiple Sclerosis Therapeutics Market, the US, Forecast ($m), 2006–2011
Figure 30: Multiple Sclerosis Therapeutics Market, the US, Forecast ($m), 2011–2019
Figure 31: Multiple Sclerosis Therapeutics Market, France, Revenue ($m), 2006–2011
Figure 32: Multiple Sclerosis Therapeutics Market, France, Forecast ($m), 2011–2019
Figure 33: Multiple Sclerosis Therapeutics Market, Germany, Revenue ($m), 2006–2011
Figure 34: Multiple Sclerosis Therapeutics Market, Germany, Forecast ($m), 2011–2019
Figure 35: Multiple Sclerosis Therapeutics Market, Italy, Revenue ($m), 2006–2011
Figure 36: Multiple Sclerosis Therapeutics Market, Italy, Forecast ($m), 2011–2019
Figure 37: Multiple Sclerosis Therapeutics Market, Spain, Revenue ($m), 2006–2011
Figure 38: Multiple Sclerosis Therapeutics Market, Spain, Forecast ($m), 2011–2019
Figure 39: Multiple Sclerosis Therapeutics Market, the UK, Revenue ($m), 2006–2011
Figure 40: Multiple Sclerosis Therapeutics Market, the UK, Forecast ($m), 2011–2019
Figure 41: Multiple Sclerosis Therapeutics Market, Japan, Revenue ($m), 2006–2011
Figure 42: Multiple Sclerosis Therapeutics Market, Japan, Forecast ($m), 2011–2019
Figure 43: KOL Insights, Unmet Need for MS Treatment
Figure 44: Opportunity and Unmet Need in the Multiple Sclerosis Therapeutics Market, 2011
Figure 45: Multiple Sclerosis Therapeutics, Strategic Competitor Assessment, 2010
Figure 46: Mechanism of Action of Fingolimod
Figure 47: Cellular Targets of Fingolimod
Figure 48: Chemical Structure of Gilenya
Figure 49: Leucocyte Trafficking Mediated by a4-integrins
Figure 50: Multiple Sclerosis Therapeutics – Pipeline by Phase of Development, 2011
Figure 51: Multiple Sclerosis Therapeutics, Technology Trends Analytics Framework, 2011
Figure 52: Multiple Sclerosis Pipeline, Technology Trends Analytics Framework, Description, 2011
Figure 53: Multiple Sclerosis Therapeutics, Pipeline by Mechanism of Action, 2011
Figure 54: KOL Insights, Pipeline Drug - Aubagio
Figure 55: KOL Insights, Pipeline Drug - RG1594
Figure 56: KOL Insights, Pipeline Drug - Laquinimod
Figure 57: KOL Insights, Pipeline Drug - Daclizumab
Figure 58: KOL Insights, Pipeline Drug - BG-12
Figure 59: KOL Insights, Pipeline Drug - Lemtrada
Figure 60: KOL Insights, Pipeline Drugs
Figure 61: KOL Insights, Challenges in the Development of MS drugs
Figure 62: Multiple Sclerosis Therapeutics, Clinical Trials by Country, 2012
Figure 63: Multiple Sclerosis Therapeutics, Clinical Trials by Phase (%), 2012
Figure 64: Multiple Sclerosis Therapeutics, Clinical Trials by Status (%), 2012
Figure 65: Multiple Sclerosis Therapeutics, Overall Sponsors (%), 2012
Figure 66: Multiple Sclerosis Therapeutics, Prominent Sponsors (%), 2012
Figure 67: Multiple Sclerosis Therapeutics, Top companies participating in Therapeutics Clinical Trials, 2012
Figure 68: Multiple Sclerosis Therapeutics Market, Drivers and Restraints, 2011
Figure 69: Implications for Future Market Competition in the Multiple Sclerosis Therapeutics Market, 2011
Figure 70: GlobalData Market Size Estimation
Figure 71: GlobalData Market Forecasting Model

GlobalData, the industry analysis specialist, has released its new report, “Multiple sclerosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global multiple sclerosis therapeutics market. The report identifies the key trends shaping and driving the global market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global multiple sclerosis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Multiple Sclerosis Therapeutics Market is Forecast to Show Slow Growth through to 2019

GlobalData estimates that the global Multiple Sclerosis (MS) therapeutics market was valued at $9,237m in 2011. The global MS therapeutics, which includes Disease Modifying Drugs (DMDs) and drugs for symptom management, is forecast to grow at a Compound Annual Growth Rate (CAGR) of 3.2% over the next eight years, to reach $11,914m by 2019. The rapid growth of the market during 2006-2011 (13.6% CAGR) was mainly due to the growth in diagnosed and treated patients. The treated patient pool registered rapid growth due to the introduction of new diagnostic criteria called the McDonald criteria, which integrated MRI findings into clinical assessments and resulted in a greater number of confirmed MS diagnoses. In addition, the understanding of the disease’s pathogenesis has improved.

The current MS therapeutics market includes DMDs approved for the management of Relapse-Remitting MS (RRMS) and drugs for symptom management. At present there are no approved drugs for the progressive stages of the disease. The DMDs prescribed for MS include four interferons: Avonex, Betaseron, Extavia and Rebif. Betaseron (US) is available as Betaferon in Europe and Japan. Other DMDs include Copaxone, Tysabri, Ampyra and Gilenya (recently launched). Gilenya is the first oral drug introduced in the market. The RRMS patients account for approximately 45% of the total MS patients. The drugs for symptom management include antidepressants, spasmolytics along with drugs for managing pain, fatigue, inflammation and so on. In the absence of any approved drugs for the progressive stages of the disease, the drugs for symptom management are prescribed.

The MS therapeutics market is expected to witness slow growth (in terms of CAGR) through the forecast period to 2019 in comparison with the historical period 2006-2011. In 2011, the US accounted for more than half of the global MS therapeutics market. The slow growth in the market is the result of the cumulative effect of both positive and negative factors within the market. The patent expiry of Copaxone (expected US patent expiry 2014 and expected European patent expiry 2015) is expected to negatively impact the US market; Copaxone has a high cost of therapy and has a strong presence in the US market. However, the introduction of pipeline products will neutralize the value erosion of the market, resulting in slow growth through to 2019. Aubagio (teriflunamide), Dimethyl Fumarate (BG-12), Daclizumab, RG1594 (ocrelizumab) and Lamtrada (alemtuzumab) are the novel late stage pipeline products likely to enter the market through to 2019.

The launch of new pipeline products is expected to change the present market scenario, which is mainly dependant on injectable formulations (such as Avonex, Betaseron/Betaferon, Rebif, Copaxone, and Tysabri). These drugs need to be injected frequently, and their dose frequency ranges from daily to weekly administration. Within the new drugs some are oral formulations (Aubagio and BG-12) and some are injectable formulations (daclizumab, ocrelizumab and alemtuzumab) and all require dosing either once a month or once every six months. Therefore, these drugs are expected to be well-tolerated and improve patient compliance. In addition to this, these products are expected to enter the market at a price lower than the price of current products. Some of these products have shown superior efficacy (BG-12, Lamtrada) in clinical trails compared to currently approved products (Copaxone and Rebif). The entry of new drugs is likely to result in a shift in patient share.

Sanofi
Merck KGaA/Merck Serono
Biogen Idec
Teva Pharmaceutical Industries (Teva)
Nuron Biotech
F. Hoffmann-La Roche (Roche)
Teijin Pharma
Accentia Biopharmaceuticals
AB Science
Abbott

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos